Dr. Michael Gibson M.S., M.D.

C. Michael Gibson M.S., M.D., pioneered our understanding of the open artery and the open microvasculature hypothesis in the setting of heart attack. As an innovator, Gibson invented measures of coronary blood flow that are widely used today, the TIMI frame count (cited 2,636 times), the TIMI myocardial perfusion grade (cited 1,246 times).

Gibson is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School. Gibson founded PERFUSE in 1987 which served as the TIMI Data coordinating center that coordinated data for the first 50 TIMI trials. The Baim institute was formerly known as Harvard Clinical Research Institute and was founded in 2000. The combined institutes have led over 1,250 studies, published 5,500 manuscripts in peer review literature (including 144 in the New England Journal) and have led 70 FDA submissions from their network of 7,000 sites in 57 countries worldwide. Since 2014, Gibson has consistently been ranked as one of the world’s most highly cited authors in all of science by Thomson Reuters. In 2021, he was named one of the Fifty of the Most Influential Voices in Healthcare by Medika Life. His work has been cited over 163,000 times.

Gibson has led phase 1-4 clinical trials, and cardiology megatrials of over 30,000 patients which eventuate in international approval of drugs like prasugrel, rivaroxaban, betrixaban and andexanet as well as devices such as one that alarms to alert a patient to heart attack.

Gibson is currently leading the first large “Virtual” randomized trial which uses apps and the internet to eliminate “bricks and mortar” and is being conducted at 1% of the usual cost. The HEARTLINE trial of the Apple watch randomized 32,000 patients and is one of the largest randomized patient trials in cardiology history. Gibson and his team will be operationalizing many of the trial efforts evaluating Milvexian, a Factor Xi inhibitor across a variety of disease states (50,000 patients with ACS, AF, or Stroke). Gibson also is leading the AEGIS 2 trial evaluating the effectiveness of an Apo A1 infusion (the building block of good cholesterol or HDL) in 18,200 patients following an MI.

Dr. Gibson is a practicing interventional cardiologist who has held numerous leadership positions in medicine including positions as a Coronary Care Unit Director, a Cardiac Catheterization Laboratory Director, a Chief of Cardiology at Harvard Medical School affiliated hospitals and as a Vice Chairman of Medicine at a hospital of over 1,000 physicians. For years, Gibson has been chosen as one of Boston’s Top Doctors & U.S. News & World Report also lists Gibson as one of America’s top doctors.

Dr. Gibson obtained his BS, MS, and MD degrees at the University of Chicago where he was a Phi Beta Kappa and AOA graduate and was a starting half back. He then went on to do his internship, residency and chief residency at the Brigham and Women’s Hospital and his cardiology fellowship at the Beth Israel Deaconess Medical Center both at Harvard Medical School.

Gibson founded WikiDoc.org and WikiPatient.org, widely viewed open-source textbooks of medicine. He is Editor-In-Chief of >2,200 active contributors who have edited the content of over 100,000 chapters millions of times over the past 15 years. Gibson also founded www.clinicaltrialresults.org and has conducted >2,600 TV / video interviews. Gibson serves as Chief Medical Correspondent for the American College of Cardiology. Gibson has over 435,000 followers on social media where he is a leading influencer, second only to Sanjay Gupta in some polls. Cardiology topics on twitter were queried in May of 2020 using the Right Relevance application programming interface (API). Gibson was ranked the number 1 cardiology influencer (Onoriode Kesiena, Henry K Onyeaka, Setri Fugar, Alexis K Okoh, Annabelle Santos Volgman. The top 100 Twitter influencers in cardiology[J]. AIMS Public Health, 2021, 8(4): 743-753. doi: 10.3934/publichealth.2021058)

Gibson is an at large member of the FDA’s cardiorenal panel having served as a standing member from 2017 to 2021.

He is an accomplished artist whose work is held in numerous collections.